QQQ   416.47 (+0.44%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
QQQ   416.47 (+0.44%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
QQQ   416.47 (+0.44%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
QQQ   416.47 (+0.44%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
NASDAQ:OABI

OmniAb (OABI) Stock Price, News & Analysis

$4.70
+0.03 (+0.64%)
(As of 12:35 PM ET)
Today's Range
$4.62
$4.70
50-Day Range
$4.59
$6.33
52-Week Range
$3.14
$6.72
Volume
123,286 shs
Average Volume
465,822 shs
Market Capitalization
$550.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

OmniAb MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
91.5% Upside
$9.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of OmniAb in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.17 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

427th out of 907 stocks

Commercial Physical Research Industry

7th out of 12 stocks

OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
RBC Capital Remains a Buy on OmniAb (OABI)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Benchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)
OmniAb’s Market Potential and Financial Stability Affirm Buy Rating
Recap: OmniAb Q4 Earnings
2 Speculative Small-Cap Biotech Stocks You Should Know About
OmniAb to Participate in Two Investor Conferences in March
OmniAb Inc OABI
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+92.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-50,620,000.00
Net Margins
-148.16%
Pretax Margin
-188.39%

Debt

Sales & Book Value

Annual Sales
$34.16 million
Book Value
$2.69 per share

Miscellaneous

Free Float
108,927,000
Market Cap
$547.00 million
Optionable
Optionable
Beta
-0.18
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 51)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 56)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 55)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 66)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller

OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

4 Wall Street research analysts have issued 1 year target prices for OmniAb's shares. Their OABI share price targets range from $7.00 to $11.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 91.5% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2024?

OmniAb's stock was trading at $6.17 at the start of the year. Since then, OABI shares have decreased by 23.8% and is now trading at $4.70.
View the best growth stocks for 2024 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OABI earnings forecast
.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. The firm earned $4.82 million during the quarter, compared to analyst estimates of $6.94 million. OmniAb had a negative net margin of 148.16% and a negative trailing twelve-month return on equity of 15.41%.

What ETF holds OmniAb's stock?

iShares Genomics Immunology and Healthcare ETF holds 161,593 shares of OABI stock, representing 0.59% of its portfolio.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.64%), Allspring Global Investments Holdings LLC (0.07%), Mesirow Financial Investment Management Inc. (0.03%) and Trivant Custom Portfolio Group LLC (0.01%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners